Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease

European Journal of Echocardiography

Volumn 12, Issue 9, 2011, Pages 671-677

  Zamorano, José ^a   Serra, Viviana ^a   De Isla, Leopoldo Pérez ^a   Feltes, Gisela ^a   Calli, Andrea ^a   Barbado, F Javier ^a   Torras, Joan ^a   Hernandez, Salvador ^a   Herrera, Julio ^a   Herrero, Jose A ^a   Pintos, Guillem ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cardiomyopathy; Enzyme replacement therapy; Fabry disease

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; ISOENZYME;

ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEPTUM NUCLEUS; TISSUE DOPPLER IMAGING; ADOLESCENT; ADULT; AGED; CHILD; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; MIDDLE AGED; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ISOENZYMES; MIDDLE AGED; VENTRICULAR SEPTUM; YOUNG ADULT;

EID: 84856009441     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jer109     Document Type: Article

References (42)

1. Kint J. Fabry's disease: alpha-galactosidase deficiency. Science 1970;167:1268-9.
2. Brady R, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276:1163-7.
3. Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003;162:767-72. (Pubitemid 37410024)
4. Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ et al. Pediatric Fabry disease. Pediatrics 2005;115:e344-55 (Epub Feb 2005). (Pubitemid 43373019)
5. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006;95:86-92. (Pubitemid 43041735)
6. Clarke JT. Narrative review: Fabry disease. Ann Intern Med 2007;146:425-33. (Pubitemid 351650579)
7. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-24. (Pubitemid 34023880)
8. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007;9:34-45. (Pubitemid 46115959)
9. Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, Osterziel KJ. The heart in Anderson Fabry disease. Z Kardiol 2002;91:786-95. (Pubitemid 36015555)
10. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007;93:528-35. (Pubitemid 46631530)
11. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-35. (Pubitemid 47343855)
12. Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker Wet al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005;26: 1221-7. (Pubitemid 40863129)
13. Weidemann F, Niemann M, Herrmann S, Kung M, Stork S, Waller C et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J 2007;28:3020-6. (Pubitemid 350262257)
14. Hasegawa H, Takano H, Shindo S, Takeda S, Funabashi N, Nakagawa K et al. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease. Circulation 2006;113:e720-1.
15. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001;104:128-30. (Pubitemid 32655824)
16. De Backer J, Matthys D, Gillebert TC, De Paepe A, De Sutter J. The use of Tissue Doppler Imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies. Eur J Echocardiogr 2005;6:243-50. Epub 2004 Nov 5. (Pubitemid 40903640)
17. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue doppler imaging. Circulation 2003;107:1978-84. (Pubitemid 36506070)
18. Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, Pintos G. et al. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 2009;132:38-44.
19. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 1987;9:II19-26.
20. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285:2743-9. (Pubitemid 32525371)
21. Sadick N, Thomas L. Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study. Heart Lung Circ 2007;16:200-6. (Pubitemid 46760677)
22. Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 2006;47:1663-71. Epub 2006 Mar 29. (Pubitemid 44313825)
23. Nagueh SF, McFalls J, Meyer D, Hill R, Zoghbi WA, Tam JW et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003;108:395-8. (Pubitemid 36935530)
24. Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 2001;24:75-83. (Pubitemid 33061636)
25. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16. (Pubitemid 32634266)
26. Barbey F, Hayoz D, Widmer U, Burnier M. Efficacy of enzyme replacement therapy in Fabry disease. Curr Med Chem Cardiovasc Hematol Agents 2004;2: 277-86. (Pubitemid 39200172)
27. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2005;21:345-54. (Pubitemid 43159987)
28. Breunig F, Wanner C. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J Nephrol 2008;21:32-7. (Pubitemid 351780571)
29. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coughlan G, Brookes J et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 2008;94:153-8 (epub May 2007). (Pubitemid 351211719)
30. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 2003;26:617-27. (Pubitemid 38008966)
31. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34: 838-44. (Pubitemid 39657931)
32. Ries M, Clarke JTR, Whybra C, Timmons M, Robinson C, Schlaggar BL et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006;118:924-32. (Pubitemid 46091613)
33. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108: 1299-301. (Pubitemid 37174405)
34. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D et al. Enzyme replacement therapy with agalsidase b improves cardiac involvement in Fabry's disease. Clin Genet 2004;66:158-65. (Pubitemid 39117524)
35. Pisani A, Spinelli L, Sabbatini M, Andreucci MV, Procaccini D, Abbaterusso C et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 2005;46:120-7. (Pubitemid 40848440)
36. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006;92:357-60. Epub 5 Aug 2005.
37. Kalliokoski RJ, Kantola I, Kalliokoski KK, Engblom E, Sundell J, Hannukainen JC et al. The effect of 12-months enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis 2006;29:112-8.
38. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann Wet al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006;97:1515-8.
39. Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 2007;61:293-302.
40. Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008;130:367-73.
41. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-48. (Pubitemid 44402030)
42. Desnick RJ, Ioannou YA, Eng CM. Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill; 1995. p2741-84.